» Articles » PMID: 30208210

Radiation and Second Primary Thyroid Cancer Following Index Head and Neck Cancer

Overview
Journal Laryngoscope
Date 2018 Sep 13
PMID 30208210
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives/hypothesis: Radiation is thought to increase risk of developing second primary thyroid cancer (SPTC). This study estimated the rate of SPTC following index head and neck cancer (HNC) and determined whether radiation treatment among HNC survivors increased SPTC risk.

Study Design: Retrospective data analysis.

Method: The Surveillance, Epidemiology, and End Results database (1975-2014) was queried for cases of index HNC (N = 127,563) that developed SPTC. Adjusted multivariable competing risk proportional hazards model tested risk of developing a SPTC following index HNC. Sensitivity analyses using proportional hazards models were also performed restricting data to patients who 1) received both radiation and chemotherapy and 2) radiation alone.

Results: Only 0.2% of index HNC survivors (n = 229) developed SPTC, yielding a rate of 26.1 per 100,000 person-years. For every increasing year of age at diagnosis, patients were 3% less likely to develop an SPTC (adjusted hazard ratio [aHR] = 0.97, 95% CI: 0.96-0.98). Males were also less likely to develop an SPTC (aHR = 0.73, 95% CI: 0.55-0.96). Radiation (aHR = 0.92, 95% CI: 0.68-1.25), surgery (aHR = 0.79, 95% CI: 0.56-1.11), and chemotherapy (aHR = 1.13, 95% CI: 0.76-1.69) were not significantly associated with developing SPTC. The sensitivity models also did not find an association between treatment and risk of SPTC.

Conclusions: Rate of developing SPTC following index HNC was very low, and previous exposure to radiation did not significantly increase risk in our study population. More studies are needed to understand the increasing incidence of thyroid cancer across the United States.

Level Of Evidence: NA Laryngoscope, 129:1014-1020, 2019.

Citing Articles

Polymorphisms of DNA Repair Genes in Thyroid Cancer.

Gielecinska A, Kciuk M, Kolat D, Kruczkowska W, Kontek R Int J Mol Sci. 2024; 25(11).

PMID: 38892180 PMC: 11172789. DOI: 10.3390/ijms25115995.


Risk of second primary thyroid cancer in cancer survivors.

Yuan Y, Sun P, Xiao H, Li L, Li J, Ai X Sci Rep. 2024; 14(1):12478.

PMID: 38816510 PMC: 11139851. DOI: 10.1038/s41598-024-63155-z.


Latency Trend Analysis as a Guide to Screening Malignancy Survivors for Second Primary Thyroid Cancer.

Hussein M, Mueller L, Issa P, Haidari M, Trinh L, Toraih E Biomedicines. 2022; 10(8).

PMID: 36009531 PMC: 9406053. DOI: 10.3390/biomedicines10081984.


Deciphering the Risk of Developing Second Primary Thyroid Cancer Following a Primary Malignancy-Who Is at the Greatest Risk?.

Trinh L, Crawford A, Hussein M, Zerfaoui M, Toraih E, Randolph G Cancers (Basel). 2021; 13(6).

PMID: 33808717 PMC: 8003482. DOI: 10.3390/cancers13061402.